Last updated: May 5, 2026
Who manufactures ZYPREXA RELPREVV (olanzapine pamoate) and where is it made?
ZYPREXA RELPREVV is marketed by Eli Lilly and Company. The drug product uses olanzapine pamoate, which is an API + pamoate salt formulation designed for long-acting intramuscular (IM) delivery.
At the product level, “supplier” in regulated drug terms maps to:
- Marketing authorization holder / NDA holder (responsible for product overall)
- Drug substance (API) manufacturers (olanzapine and pamoate salt manufacture)
- Drug product manufacturers (sterile suspension, filling, packaging)
- Excipients suppliers (used to form the injectable formulation)
- Packaging suppliers (vials/syringes/closure systems)
What is the legally relevant “supplier set” behind ZYPREXA RELPREVV?
For branded injectable products, the legally relevant supplier set appears in:
- FDA Center for Drug Evaluation and Research (CDER) labeling and listing
- FDA’s Drug Registration and Listing System (DRLS)
- FDA product-specific databases that identify listed establishments
- ANDA/BLA-type public chemistry/manufacturing disclosure only when applicable
However, the user request is limited to “Suppliers for the pharmaceutical drug: ZYPREXA RELPREVV” without specifying whether the target is:
- manufacturing establishments (listed FDA facilities),
- active ingredient suppliers,
- excipient/closure suppliers, or
- contract manufacturing organizations (CMOs) for sterile fill-finish.
With only the product name provided, a complete and accurate supplier list cannot be produced without risking factual errors.
Which suppliers can be asserted from public, product-level facts alone?
From available public product-level facts, the only non-facility-specific supplier role that can be stated without manufacturing-detail sourcing is:
- Eli Lilly and Company: marketing authorization holder for ZYPREXA RELPREVV (brand owner and NDA holder).
No API manufacturer, no drug product (fill-finish) site, and no excipient/packaging vendor list can be stated accurately from the product name alone.
What does “supplier” mean for investors and R&D teams tracking supply-chain risk?
For long-acting injectables like ZYPREXA RELPREVV, the supply-chain risk concentrates in a small number of categories:
| Supply chain node |
Why it matters for long-acting injectables |
| Drug substance (API) and salt formation |
Controls particle characteristics, impurity profile, and pamoate conversion consistency |
| Sterile manufacturing and sterile suspension readiness |
Injectable products require tight controls on aseptic processing and handling |
| Suspension quality attributes |
Long-acting products depend on consistent particle size distribution and re-suspension performance |
| Primary packaging components |
Vial/closure compatibility affects stability, extractables, and dosing accuracy |
How to operationalize supplier due diligence for ZYPREXA RELPREVV
A due diligence sprint normally requires mapping:
- Listed manufacturing establishments for the drug product (drug product manufacturing and sterile operations)
- Listed establishments for drug substance (API manufacturing and pamoate salt steps)
- Authorized suppliers of critical excipients and any custom-manufactured components
- Packaging component suppliers used for primary containers and closures
This is typically done via FDA listing data plus labeling/CMC references tied to the specific product strength and dosage form.
What can’t be filled in from the current input
A supplier table for ZYPREXA RELPREVV that names specific manufacturing sites, API manufacturers, or excipient/packaging vendors requires sourcing from:
- FDA DRLS establishment listings,
- product-specific CMC references, and
- public regulatory submissions tied to the exact product code.
Without that sourcing, any named list would be speculative and not fit a hard-data requirement.
Key Takeaways
- Eli Lilly and Company is the marketing authorization holder for ZYPREXA RELPREVV.
- A complete supplier list (API manufacturers, drug product fill-finish CMOs, excipient vendors, packaging suppliers) cannot be stated accurately from the product name alone.
- For long-acting injectables, the supplier-risk focus is API/salt formation, sterile suspension manufacturing, and primary packaging compatibility.
FAQs
-
Who is the manufacturer of ZYPREXA RELPREVV?
Eli Lilly and Company is the marketing authorization holder for the product.
-
Who supplies the olanzapine pamoate active ingredient?
Specific API supplier/manufacturing establishments require FDA listing/CMC sourcing tied to the product.
-
Which companies perform the sterile fill-finish for ZYPREXA RELPREVV?
The drug product manufacturing and fill-finish sites must be pulled from FDA establishment listings for the exact product.
-
What types of vendors are included in a ZYPREXA RELPREVV supplier map?
API/drug substance manufacturers, sterile drug product manufacturers, critical excipient vendors, and primary packaging component suppliers.
-
What is the best way to build a defensible supplier list for this product?
Start with FDA establishment listings for the product and drug substance, then validate against product-specific regulatory CMC documentation.
References
- FDA. Drug Registration and Listing System (DRLS). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/drls/ (accessed 2026-05-06)
